In conclusion, we have found low expression of MPC1 and MPC2 in agressive prostate cancer cell line, and also discovered that negative expression of MPC complex is significantly associated with unfavorable clinicopathological features in PCA samples and shorter survival in PCA patients. Here, MPC2 is linked to posterior cortical atrophy.